临床研究视角下的SGLT2抑制剂:糖尿病心力衰竭治疗的“破界先锋”
SGLT2 inhibitor from a clinical research perspective: boundary-break- ing pioneer in the treatment of diabetic heart failure
大量的临床试验证实,使用钠-葡萄糖协同 转运蛋白 2 抑制剂 (sodium- glucose co-trans- porter 2 inhibitor,SGLT2i)治疗可显著降低糖尿 病患者的心力衰竭(heart failure,HF)发生风险,并改善已合并HF患者的临床结局。本综述基于循证医学,总结目前对支持糖尿病 HF 患者 使用 SGLT2i 临床获益的理解和证据,为糖尿病 HF 的临床用药提供新策略和依据。
Extensive clinical trials have demonstrated that treatment with sodium-glucose co- transporter 2 inhibitor (SGLT2i) significantly re- duces the risk of heart failure (HF) in patients with diabetes and improves clinical outcomes in those with established HF. Grounded in evidence-based medicine, this review summarizes current under- standing and supporting evidence for the clinical benefits of SGLT2i in diabetic HF, providing new therapeutic strategies and rationale for its manage- ment.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
中国医师协会心血管内科医师分会, 中国心衰中心 联盟, 《慢性心力衰竭"新四联"药物治疗临床决策路 径专家共识》工作组. 慢性心力衰竭"新四联"药物治 疗临床决策路径专家共识[J].中国循环杂志, 2022, 37(8): 769-781. |
江苏省科技厅重点研发项目(BE2022780)
/
| 〈 |
|
〉 |